Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program

Jean Addington¹, Lu Liu¹, Monica Chu¹, Karl Jungert¹, Nora Penzel^{2

3

4}, Ofer Pasternak^{2

3

5}, Emily Farina⁶, Ricardo E Carrion^{7

8

9}, Cheryl M Corcoran¹⁰, Vijay A Mittal¹¹, Gregory P Strauss¹², Alison R Yung^{13

14}, Luis Alameda^{15

16

17}, Celso Arango¹⁸, Owen Borders³, Sylvain Bouix¹⁹, Nicholas J K Breitborde²⁰, Matthew R Broome^{21

22}, Kristin S Cadenhead²³, Rolando I Castillo-Passi^{24

25}, Eric Yu Hai Chen²⁶, Jimmy Choi²⁷, Michael J Coleman³, Philippe Conus²⁸, Covadonga M Diaz-Caneja¹⁸, Lauren M Ellman²⁹, Paolo Fusar Poli^{17

30}, Pablo A Gaspar²⁴, Carla Gerber^{31

32}, Louise Birkedal Glenthøj^{33

34}, Leslie E Horton³⁵, Christy Lai Ming Hui²⁶, Joseph Kambeitz³⁶, Lana Kambeitz-Ilankovic^{36

37}, Tina Kapur⁵, Sinead Kelly³, Melissa J Kerr³⁸, Matcheri S Keshavan³⁹, Minah Kim^{40

41}, Sung-Wan Kim^{42

43}, Nikolaos Koutsouleris^{4

17

44}, Jun Soo Kwon^{41

45}, Kerstin Langbein⁴⁶, Kathryn E Lewandowski^{47

48}, Daniel Mamah⁴⁹, Patricia J Marcy⁷, Daniel H Mathalon^{50

51}, Catalina Mourgues⁶, Merete Nordentoft^{33

52}, Angela R Nunez^{6

53}, Godfrey D Pearlson^{6

54}, Jesus Perez^{55

56}, Diana O Perkins⁵⁷, Albert R Powers 3rd^{6

53}, Jack Rogers^{21

58}, Fred W Sabb³¹, Jason Schiffman⁵⁹, Johanna Seitz-Holland^{2

3}, Jai L Shah^{60

61}, Steven M Silverstein⁶², Stefan Smesny⁴⁶, William S Stone⁶³, Judy L Thompson⁶⁴, Rachel Upthegrove^{21

65}, Swapna Verma^{66

67}, Jijun Wang⁶⁸, Daniel H Wolf⁶⁹, Tianhong Zhang⁷⁰, Lauren Addamo^{38

71}, Kate Buccilli^{38

71}, Dominic Dwyer^{38

71}, Sophie Todd^{38

71}, Youngsun T Cho⁶, Clara Fontenau⁶, Zailyn Tamayo⁶, Carrie E Bearden⁷², John M Kane^{73

74}, Patrick D McGorry^{38

71}, Rene S Kahn¹⁰, Martha E Shenton^{2

75}, Scott W Woods⁶; Accelerating Medicines Partnership® Schizophrenia Nelson Barnaby; Monica E Calkins⁶⁹

Affiliations

¹ Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, AB T2N 4Z6, Canada.
² Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, United States.
³ Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
⁴ Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, 80336 Munich, Germany.
⁵ Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States.
⁶ Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, United States.
⁷ Northwell, Glen Oaks, NY 11004, United States.
⁸ Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, United States.
⁹ Institute of Behavioral Science, Feinstein Institutes of Medical Research, Manhasset, NY 11030, United States.
¹⁰ Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
¹¹ Department of Psychology, Northwestern University, Evanston, IL 60201, United States.
¹² Department of Psychology, University of Georgia, Athens, GA 30602, United States.
¹³ Institute of Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, Geelong, VIC, 3220, Australia.
¹⁴ School of Health Sciences, University of Manchester, Manchester, M139PL, United Kingdom.
¹⁵ National Psychosis Unit, South London and Maudsley NHS Foundation Trust, London, SE5 8AF, United Kingdom.
¹⁶ Service of General Psychiatry, Treatment and Early Intervention in Psychosis Program, Lausanne University Hospital (CHUV), 1003, Lausanne, Switzerland.
¹⁷ Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, SE5 8AF, United Kingdom.
¹⁸ Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, Instituto de Salud Carlos III, School of Medicine, Universidad Complutense, 28009 Madrid, Spain.
¹⁹ Department of Software Engineering and Information Technology, École de Technologie Supérieure, Montréal, QC HC3 1K3, Canada.
²⁰ Department of Psychiatry and Behavioral Health, Early Psychosis Intervention Center (EPICENTER), College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States.
²¹ Institute for Mental Health, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
²² Early Intervention for Psychosis Services, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, B13 8QE, United Kingdom.
²³ University of California, San Diego, La Jolla, CA 92104, United States.
²⁴ Department of Psychiatry, University of Chile, 833011 Santiago, Chile.
²⁵ Department of Neurology and Psychiatry, Clínica Alemana - Universidad del Desarrollo, 7610658 Santiago, Chile.
²⁶ Department of Psychiatry, School of Clinical Medicine, LKF Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.
²⁷ Olin Neuropsychiatry Research Center, Hartford HealthCare Behavioral Health Network, Hartford, CT 06106, United States.
²⁸ General Psychiatry Service, Treatment and Early Intervention in Psychosis Program (TIPP-Lausanne), Lausanne University Hospital and University of Lausanne, 1003 Lausanne, Switzerland.
²⁹ Department of Psychology & Neuroscience, Temple University, Philadelphia, PA 19122-6085, United States.
³⁰ Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.
³¹ Prevention Science Institute, University of Oregon, Eugene, OR 97401, United States.
³² Oregon Research Institute, Springfield, OR 97477, United States.
³³ VIRTU Research Group, Mental Health Copenhagen, University of Copenhagen, 2900 Copenhagen, Denmark.
³⁴ Department of Psychology, University of Copenhagen, 1353 Copenhagen, Denmark.
³⁵ Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States.
³⁶ Department of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
³⁷ Faculty of Psychology and Educational Sciences, Department of Psychology, Ludwig-Maximilian-University, 80802 Munich, Germany.
³⁸ Orygen, Parkville, VIC, 3052 Australia.
³⁹ Department of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, United States.
⁴⁰ Department of Neuropsychiatry, Seoul National University Hospital, Seoul 03082, South Korea.
⁴¹ Department of Psychiatry, Seoul National University College of Medicine, Seoul 03080, South Korea.
⁴² Department of Psychiatry, Chonnam National University Medical School, Gwangju 61469, South Korea.
⁴³ Mindlink, Gwangju Bukgu Mental Health Center, Gwangju 61005, South Korea.
⁴⁴ Max Planck Institute of Psychiatry, 80804 Munich, Germany.
⁴⁵ Department of Psychiatry, Hanyang University Hospital, Seoul 04763, South Korea.
⁴⁶ Department of Psychiatry and Psychotherapy, Jena University Hospital, 07743 Jena, Germany.
⁴⁷ Psychotic Disorders Division, McLean Hospital, Belmont, MA 02478, United States.
⁴⁸ Department of Psychiatry, Harvard Medical School, Boston, MA 02115, United States.
⁴⁹ Department of Psychiatry, Washington University Medical School, St. Louis, MO 63110, United States.
⁵⁰ Department of Psychiatry and Behavioral Sciences and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94121, United States.
⁵¹ Mental Health Service 116D, Veterans Affairs San Francisco Health Care System, San Francisco, CA 94121, United States.
⁵² Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark.
⁵³ Connecticut Mental Health Center, New Haven, CT 06519, United States.
⁵⁴ Olin Neuropsychiatry Research Center, Hartford Hospital, Hartford, CT 06106, United States.
⁵⁵ CAMEO, Early Intervention in Psychosis Service, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, Cambridgeshire, CB4 1PX, United Kingdom.
⁵⁶ Department of Medicine, Institute of Biomedical Research (IBSAL), Universidad de Salamanca, 37007 Salamanca, Spain.
⁵⁷ Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, United States.
⁵⁸ Centre for Human Brain Health, University of Birmingham, Birmingham, B152TT United Kingdom.
⁵⁹ Department of Psychological Science, University of California, Irvine, Irvine, CA, United States.
⁶⁰ Douglas Research Centre, Montréal, QC H4H 1R3, Canada.
⁶¹ Department of Psychiatry, McGill University, Montréal, QC H3A 1A1, Canada.
⁶² Department of Psychiatry, University of Rochester Medical Center, Rochester, NY 14642, United States.
⁶³ Department of Psychiatry, Beth Israel Deaconess Medical Center, Massachusetts Mental Health Center and Harvard Medical School, Boston, MA 02115, United States.
⁶⁴ Departments of Psychiatry and Neuroscience, University of Rochester Medical Center, Rochester, NY 14642, United States.
⁶⁵ Department of Psychiatry, University of Oxford, Oxford, 0X37JX United Kingdom.
⁶⁶ Institute of Mental Health, 539747, Singapore.
⁶⁷ Duke-NUS Medical School, 169857, Singapore.
⁶⁸ Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 20030, China.
⁶⁹ Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19063, United States.
⁷⁰ Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China.
⁷¹ Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, 3052, Australia.
⁷² Departments of Psychiatry and Biobehavioral Sciences and Psychology, Semel Institute for Neuroscience and Human Behavior; University of California, Los Angeles, Los Angeles, CA 90095, United States.
⁷³ Department of Psychiatry, Donald and Barbara Zucker School of Medicine, Hempstead, NY 11549, United States.
⁷⁴ Feinstein Institute for Medical Research, Manhasset, NY 11030, United States.
⁷⁵ Department of Psychiatry and Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States.

PMID: 40861307
PMCID: PMC12377803
DOI: 10.1093/schizbullopen/sgaf012

Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program

Jean Addington et al. Schizophr Bull Open. 2025.

. 2025 Aug 25;6(1):sgaf012.

doi: 10.1093/schizbullopen/sgaf012. eCollection 2025 Jan.

Authors

Affiliations

¹ Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, AB T2N 4Z6, Canada.
² Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, United States.
³ Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
⁴ Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, 80336 Munich, Germany.
⁵ Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States.
⁶ Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, United States.
⁷ Northwell, Glen Oaks, NY 11004, United States.
⁸ Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, United States.
⁹ Institute of Behavioral Science, Feinstein Institutes of Medical Research, Manhasset, NY 11030, United States.
¹⁰ Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
¹¹ Department of Psychology, Northwestern University, Evanston, IL 60201, United States.
¹² Department of Psychology, University of Georgia, Athens, GA 30602, United States.
¹³ Institute of Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, Geelong, VIC, 3220, Australia.
¹⁴ School of Health Sciences, University of Manchester, Manchester, M139PL, United Kingdom.
¹⁵ National Psychosis Unit, South London and Maudsley NHS Foundation Trust, London, SE5 8AF, United Kingdom.
¹⁶ Service of General Psychiatry, Treatment and Early Intervention in Psychosis Program, Lausanne University Hospital (CHUV), 1003, Lausanne, Switzerland.
¹⁷ Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, SE5 8AF, United Kingdom.
¹⁸ Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, Instituto de Salud Carlos III, School of Medicine, Universidad Complutense, 28009 Madrid, Spain.
¹⁹ Department of Software Engineering and Information Technology, École de Technologie Supérieure, Montréal, QC HC3 1K3, Canada.
²⁰ Department of Psychiatry and Behavioral Health, Early Psychosis Intervention Center (EPICENTER), College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States.
²¹ Institute for Mental Health, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
²² Early Intervention for Psychosis Services, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, B13 8QE, United Kingdom.
²³ University of California, San Diego, La Jolla, CA 92104, United States.
²⁴ Department of Psychiatry, University of Chile, 833011 Santiago, Chile.
²⁵ Department of Neurology and Psychiatry, Clínica Alemana - Universidad del Desarrollo, 7610658 Santiago, Chile.
²⁶ Department of Psychiatry, School of Clinical Medicine, LKF Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.
²⁷ Olin Neuropsychiatry Research Center, Hartford HealthCare Behavioral Health Network, Hartford, CT 06106, United States.
²⁸ General Psychiatry Service, Treatment and Early Intervention in Psychosis Program (TIPP-Lausanne), Lausanne University Hospital and University of Lausanne, 1003 Lausanne, Switzerland.
²⁹ Department of Psychology & Neuroscience, Temple University, Philadelphia, PA 19122-6085, United States.
³⁰ Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.
³¹ Prevention Science Institute, University of Oregon, Eugene, OR 97401, United States.
³² Oregon Research Institute, Springfield, OR 97477, United States.
³³ VIRTU Research Group, Mental Health Copenhagen, University of Copenhagen, 2900 Copenhagen, Denmark.
³⁴ Department of Psychology, University of Copenhagen, 1353 Copenhagen, Denmark.
³⁵ Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States.
³⁶ Department of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
³⁷ Faculty of Psychology and Educational Sciences, Department of Psychology, Ludwig-Maximilian-University, 80802 Munich, Germany.
³⁸ Orygen, Parkville, VIC, 3052 Australia.
³⁹ Department of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, United States.
⁴⁰ Department of Neuropsychiatry, Seoul National University Hospital, Seoul 03082, South Korea.
⁴¹ Department of Psychiatry, Seoul National University College of Medicine, Seoul 03080, South Korea.
⁴² Department of Psychiatry, Chonnam National University Medical School, Gwangju 61469, South Korea.
⁴³ Mindlink, Gwangju Bukgu Mental Health Center, Gwangju 61005, South Korea.
⁴⁴ Max Planck Institute of Psychiatry, 80804 Munich, Germany.
⁴⁵ Department of Psychiatry, Hanyang University Hospital, Seoul 04763, South Korea.
⁴⁶ Department of Psychiatry and Psychotherapy, Jena University Hospital, 07743 Jena, Germany.
⁴⁷ Psychotic Disorders Division, McLean Hospital, Belmont, MA 02478, United States.
⁴⁸ Department of Psychiatry, Harvard Medical School, Boston, MA 02115, United States.
⁴⁹ Department of Psychiatry, Washington University Medical School, St. Louis, MO 63110, United States.
⁵⁰ Department of Psychiatry and Behavioral Sciences and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94121, United States.
⁵¹ Mental Health Service 116D, Veterans Affairs San Francisco Health Care System, San Francisco, CA 94121, United States.
⁵² Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark.
⁵³ Connecticut Mental Health Center, New Haven, CT 06519, United States.
⁵⁴ Olin Neuropsychiatry Research Center, Hartford Hospital, Hartford, CT 06106, United States.
⁵⁵ CAMEO, Early Intervention in Psychosis Service, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, Cambridgeshire, CB4 1PX, United Kingdom.
⁵⁶ Department of Medicine, Institute of Biomedical Research (IBSAL), Universidad de Salamanca, 37007 Salamanca, Spain.
⁵⁷ Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, United States.
⁵⁸ Centre for Human Brain Health, University of Birmingham, Birmingham, B152TT United Kingdom.
⁵⁹ Department of Psychological Science, University of California, Irvine, Irvine, CA, United States.
⁶⁰ Douglas Research Centre, Montréal, QC H4H 1R3, Canada.
⁶¹ Department of Psychiatry, McGill University, Montréal, QC H3A 1A1, Canada.
⁶² Department of Psychiatry, University of Rochester Medical Center, Rochester, NY 14642, United States.
⁶³ Department of Psychiatry, Beth Israel Deaconess Medical Center, Massachusetts Mental Health Center and Harvard Medical School, Boston, MA 02115, United States.
⁶⁴ Departments of Psychiatry and Neuroscience, University of Rochester Medical Center, Rochester, NY 14642, United States.
⁶⁵ Department of Psychiatry, University of Oxford, Oxford, 0X37JX United Kingdom.
⁶⁶ Institute of Mental Health, 539747, Singapore.
⁶⁷ Duke-NUS Medical School, 169857, Singapore.
⁶⁸ Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 20030, China.
⁶⁹ Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19063, United States.
⁷⁰ Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China.
⁷¹ Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, 3052, Australia.
⁷² Departments of Psychiatry and Biobehavioral Sciences and Psychology, Semel Institute for Neuroscience and Human Behavior; University of California, Los Angeles, Los Angeles, CA 90095, United States.
⁷³ Department of Psychiatry, Donald and Barbara Zucker School of Medicine, Hempstead, NY 11549, United States.
⁷⁴ Feinstein Institute for Medical Research, Manhasset, NY 11030, United States.
⁷⁵ Department of Psychiatry and Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States.

PMID: 40861307
PMCID: PMC12377803
DOI: 10.1093/schizbullopen/sgaf012

Abstract

Background: This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical variables and biomarkers in a total of 2040 clinical high-risk (CHR) participants and 652 community control (CC) participants.

Methods: The dataset analyzed includes 1642 individuals at clinical high risk for psychosis and 519 CCs. Key measures include the Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the Structured Interview for Psychosis-Risk Syndromes, which determined CHR criteria and the severity of attenuated psychotic symptoms (APS). Other measures included the Structured Clinical Interview for DSM-5, scales to assess negative symptoms, depression, suicidal ideation, substance use, social and role functioning, and a selection of patient-reported outcomes.

Results: CHR participants presented with more severe ratings on all clinical measures and poorer functioning relative to the CC. There were a few significant small associations between measures of APS and other clinical measures.

Conclusion: The results from this study support previous research indicating that CHR individuals face serious clinical challenges beyond the risk of developing psychosis. Findings indicate significant associations among various clinical measures, underscoring the complex nature of the CHR population. Limitations are acknowledged, including the preliminary nature of the data and the need for more in-depth analyses from AMP SCZ papers already in progress. Future work will focus on longitudinal data and further exploration of clinical variables and their relationship with biomarkers.

Keywords: AMP SCZ; assessments; clinical high risk; clinical outcomes; community controls; psychosis.

PubMed Disclaimer

Conflict of interest statement

Dr. C. Arango has been a consultant to and/or has received honorarium and or grants from Acadia, Angelini, Biogen, Boehringer, Gideon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Rovi, Sage, Servier, Shire, Shering Plough, Sumitomo Dainippon Pharma, Sunovian, and Takeda. Dr. R. Upthegrove has received speaker fees for Otsuka and consulted to Viatris and Springer Healthcare. Dr. P. Fusar-Poli has received research funds or personal fees from Angelini, Boehringer Ingelheim, Lundbeck, Menarini, Otsuka, Sunovian, and Proxymm Science. Dr. S. Woods has received speaking fees from the American Psychiatric Association and from Medscape Features. He has been granted US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonists. He owns stock in NW PharmaTech. Dr. C. Diaz-Caneja has received grant support from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, and honoraria or travel support from Angelini, Janssen, and Viatris. Dr. Kambeitz has received speaking or consulting fees from Janssen, Boehringer Ingelheim, ROVI and Lundbeck. Patricia J. Marcy is a consultant for Otsuka and TEVA. Dr. R. S. Kahn is a consultant for Alkermes and Boehringer Ingelheim. Dr. J. Kane Consultant to or receives honoraria and/or travel support and/or speakers bureau: Alkermes, Allergan, Boehringer Ingelheim, Cerevel, Dainippon Sumitomo, H. Lundbeck, HealthRhythms, HLS Therapeutics, Indivior, Intracellular Therapies, Janssen Pharmaceutical, Johnson & Johnson, Karuna Therapeutics/Bristol Meyer-Squibb, LB Pharmaceuticals, Mapi, Maplight, Merck, Minerva, Neurocrine, Newron, Novartis, NW PharmaTech, Otsuka, Roche, Saladax, Sunovion, and Teva. Advisory Boards: Alkermes, Boehringer Ingelheim, Cerevel, Click Therapeutics, Karuna/BMS, Lundbeck, Merck, Newron, Novartis, Otsuka, Sumitomo, Teva, and Terran. Grant Support: Lundbeck, Janssen, Otsuka, Sunovion. Shareholder interests: Cerevel (public/stock), HealthRhythms (private/stock options), Karuna/BMS (public), LB Pharmaceuticals, Inc. (private/stock options), North Shore Therapeutics (private/stock), and Vanguard Research Group (private/40% owner). All other authors have declared that there are no conflicts of interest in relation to the subject of this study.

Figures

**Figure 1**
Percentages Meeting Different High-Risk Criteria from the PSYCHS. The first 4 columns refer to the 3 CAARMS Criteria of BLIPS, APS, and Trait Vulnerability, and UHR being the Total Number Meeting at Least One of the 3 CAARMS Criteria. The next 4 columns refer to the 3 SIPS Criteria of BIPS, APSS Progression and GRD, and CHR Progression being the Total Number Meeting at Least One of the 3 SIPS Criteria.

See this image and copyright information in PMC

References

1. Brady LS, Larrauri CA, Committee ASS. Accelerating medicines partnership((R)) schizophrenia (AMP((R)) SCZ): developing tools to enable early intervention in the psychosis high risk state. World Psychiatry 2023;22:42–43. 10.1002/wps.21038 - DOI - PMC - PubMed
1. Wannan CMJ, Nelson B, Addington J et al. Accelerating medicines partnership(R) schizophrenia (AMP(R) SCZ): rationale and study Design of the Largest Global Prospective Cohort Study of clinical high risk for psychosis. Schizophr Bull 2024;50:496–512. 10.1093/schbul/sbae011 - DOI - PMC - PubMed
1. Addington J, Liu L, Braun A et al. Sample ascertainment and clinical outcome measures in the accelerating medicines partnership(R) schizophrenia program. Schizophrenia (Heidelb). 2025;11:54. 10.1038/s41537-025-00556-7 - DOI - PMC - PubMed
1. Allott K, Yassin W, Alameda L et al. Cognitive assessment in the accelerating medicines partnership(R) schizophrenia program: harmonization priorities and strategies in a diverse international sample. Schizophrenia (Heidelb). 2025;11:49. 10.1038/s41537-025-00578-1 - DOI - PMC - PubMed
1. Billah T, Cho KIK, Borders O et al. Enabling FAIR data stewardship in complex international multi-site studies: data operations for the accelerating medicines partnership(R) schizophrenia program. Schizophrenia (Heidelb). 2025;11:55. 10.1038/s41537-025-00560-x - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources
- PubMed Central
- Silverchair Information Systems
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program

Affiliations

Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources

Miscellaneous